Medical News

RSS

Deal to avert gov't shutdown appears within reach

A recent short-term spending plan that emerged from the House Appropriations Committee includes millions of dollars in cuts to federal health programs. Meanwhile, congressional efforts to reach agreement on a long-term spending plan may be getting more complicated.

28 Feb 2011

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

biOasis Technologies Inc. is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest™ blood test for Alzheimer's disease.

28 Feb 2011

Viewpoints: Judge Kessler's decision; Utah is role model; Malpractice system flaws

The Republican strategy is to split the vast middle and working classes -- pitting unionized workers against nonunionized, public-sector workers against nonpublic, older workers within sight of Medicare and Social Security against younger workers who don't believe these programs will be there for them and the poor against the working middle class.

28 Feb 2011

State News: N.Y. Medicaid's compromise; Va. ups health spending; Medi-Cal ruling

One of the most familiar criticisms of the new national health care law is that it doesn't do much to contain costs. ... Cost controls are supposed to come later. "Later" has arrived now for Massachusetts' statewide plan, enacted in 2006 and similar in many ways to the federal one. Some 98 percent of all adults and nearly 100 percent of all children are covered, but costs have spiraled out of control.

28 Feb 2011

USPI fourth quarter consolidated net revenues increase 3.5% to $154.2 million

United Surgical Partners International, Inc. today announced results for the fourth quarter and year ended December 31, 2010.

28 Feb 2011

Thermo Fisher Scientific announces redemption of outstanding 3.25% Convertible Notes

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has given notice of its intention to redeem all of the outstanding 3.25% Convertible Senior Subordinated Notes due 2024 (the "Notes").

From Thermo Fisher Scientific Inc. 28 Feb 2011

Tenofovir gel may help reduce risk of HIV from anal sex

A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel could help reduce the risk of HIV from anal sex, even though the vaginal gel formulation may not be optimal for rectal use.

28 Feb 2011

Synageva supports Fourth International Rare Disease Day

Synageva BioPharma Corp., a privately held biopharmaceutical company that is developing therapeutic products for rare disorders, announced today that the company is supporting the Fourth International Rare Disease Day observance on February 28, 2011.

28 Feb 2011

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010.

28 Feb 2011

Astra Tech enters global strategic alliance with 3Shape

Astra Tech, a market leader and innovator in the field of implant dentistry and CAD/CAM abutments, announces a global strategic alliance with 3Shape A/S, the Danish-based provider of 3D scanners and CAD/CAM software solutions.

28 Feb 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it had received a net sales milestone of $2.5 million from Cowen Healthcare Royalty Partners, L.P..

28 Feb 2011

Exactech fourth quarter total revenue increases 7% to $51.8 million

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, extremities, spine and biologic materials, announced today that revenue for 2010 increased 7% to $190.5 million from $177.3 million in 2009. Diluted earnings per share for the year was $0.80 based on net income of $10.5 million.

28 Feb 2011

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review classification to its Supplemental New Drug Application (sNDA) regarding ISTODAX (romidepsin) for injection for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.

28 Feb 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

Positive results from Trius torezolid Phase 1 lung study

Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections. In this study a 200 mg dose of torezolid phosphate was administered orally once-daily for three days to healthy adult volunteers. The trial achieved its primary goal of establishing the steady-state plasma pharmacokinetics and distribution of active drug into epithelial lining fluid (ELF).

28 Feb 2011

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the first quarter ended December 31, 2010.

28 Feb 2011

FDA grants 510(k) clearance for Derma Sciences MEDIHONEY Gel Wound and Burn Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company's patent-pending MEDIHONEY® Gel Wound and Burn Dressing.

28 Feb 2011

EPA approves BioNeutral's Ygiene 206 antimicrobial disinfectant

BioNeutral Group, Inc., a specialty life science technology-based company, today announced that it has received approval and registration from the Environmental Protection Agency (EPA) in response to the Company's regulatory application for its Ygiene™ 206.

28 Feb 2011

First Edition: February 28, 2011

Today's headlines include news about the budge struggles the nation's governors continue to face -- with Medicaid spending a central issue.

28 Feb 2011

Medical News

Deal to avert gov't shutdown appears within reach

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

Viewpoints: Judge Kessler's decision; Utah is role model; Malpractice system flaws

State News: N.Y. Medicaid's compromise; Va. ups health spending; Medi-Cal ruling

USPI fourth quarter consolidated net revenues increase 3.5% to $154.2 million

Thermo Fisher Scientific announces redemption of outstanding 3.25% Convertible Notes

Tenofovir gel may help reduce risk of HIV from anal sex

Synageva supports Fourth International Rare Disease Day

Endo fourth quarter total revenues increase 31% to $511 million

Astra Tech enters global strategic alliance with 3Shape

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Exactech fourth quarter total revenue increases 7% to $51.8 million

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Positive results from Trius torezolid Phase 1 lung study

SQI Diagnostics first quarter net loss increases to $2,255,000

FDA grants 510(k) clearance for Derma Sciences MEDIHONEY Gel Wound and Burn Dressing

EPA approves BioNeutral's Ygiene 206 antimicrobial disinfectant

First Edition: February 28, 2011

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Data management challenges in scientific research

Latest News